Skip to content

Market/Novel Tech

Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV

Samsung Bioepis announced that the FDA (Food and Drug Administration) has approved the supplemental biologics license application (BLA) for Byooviz (ranibizumab-nuna) as a biosimilar product… Read More »Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV

Opus Genetics Inc., has announced the “first-in-patient” in a Phase 1/2 clinical trial for “OPGx-001” for the treatment of LCA5 retinal disease.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced its “first-in-patient” in a Phase 1/2 clinical trial for… Read More »Opus Genetics Inc., has announced the “first-in-patient” in a Phase 1/2 clinical trial for “OPGx-001” for the treatment of LCA5 retinal disease.

Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy. 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key results from a Phase 2 clinical trial, “STARLIGHT”, at the American Society of… Read More »Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy. 

Beacon Therapeutics have announced the acquisition of AGTC (NASDAQ: AGTC), supported by Syncona Ltd and Oxford Science Enterprises.

Beacon Therapeutics, based in London and Oxford, UK, have recently announced an investment of £96 million (€112 million) to fund the acquisition of AGTC (Applied… Read More »Beacon Therapeutics have announced the acquisition of AGTC (NASDAQ: AGTC), supported by Syncona Ltd and Oxford Science Enterprises.

Kiora Pharmaceuticals Inc. have announced a partnership with the Choroideremia Research Foundation for novel treatments.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), an ophthalmic pharmaceutical company based in California, and the Choroideremia Research Foundation (CRF), a non-for-profit patient organisation focused on the… Read More »Kiora Pharmaceuticals Inc. have announced a partnership with the Choroideremia Research Foundation for novel treatments.

The American Society of Retina Specialists (ASRS) has reported at least six cases of occlusive retinal vasculitis following injection of Syfovre (pegcetacoplan).

According to the ASRS Research and Safety in Therapeutics (ReST) Committee, a small number of cases of occlusive retinal vasculitis has been observed between 7… Read More »The American Society of Retina Specialists (ASRS) has reported at least six cases of occlusive retinal vasculitis following injection of Syfovre (pegcetacoplan).

FDA has declined approval of Regeneron’s higher dose (8mg) of Eylea, understood to be a review of inspection findings at a third-party filler.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics… Read More »FDA has declined approval of Regeneron’s higher dose (8mg) of Eylea, understood to be a review of inspection findings at a third-party filler.

Nanoscope Therapeutics Inc., have announced key results for Phase 2b (“RESTORE”) for the treatment of retinitis pigmentosa (RP) using optogenetic therapy. 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key data from a Phase 2b multi-centre RCT (NCT04945772) of “MCO-010” (sonpiretigene isteparvovec), an… Read More »Nanoscope Therapeutics Inc., have announced key results for Phase 2b (“RESTORE”) for the treatment of retinitis pigmentosa (RP) using optogenetic therapy. 

US “LIGHTSITE III” clinical trial data on photo-biomodulation (PBT) treatment of dry AMD has reported vision improvement for 24 months.

A US company, LumiThera Inc., based in Seattle, WA has reported summary trial data on photo-biomodulation, termed “LIGHTSITE III” study, conducted by a multi-centre clinical… Read More »US “LIGHTSITE III” clinical trial data on photo-biomodulation (PBT) treatment of dry AMD has reported vision improvement for 24 months.